A method for producing a composition comprising nanoparticles of a biologically active compound.

The present invention relates to an agent for killing HIV-1-infected cells, comprising a compound represented by formula (I):

##STR00001##

wherein Ar.sup.1 and Ar.sup.2 are the same or different and represent a substituted or unsubstituted aromatic group, and X represents —CH.sub.2O— or —CH═CH—, its salt, or their solvate, and a combined preparation for simultaneous, separate, or sequential administration in treating or preventing HIV-1 infection, comprising two separate preparations: (a) a preparation comprising a compound represented by the formula (I), its salt, or their solvate, and (b) a preparation comprising an anti-HIV-1 drug.

The present invention relates to an agent for killing HIV-1-infected cells, comprising a compound represented by formula (I):

##STR00001##

wherein Ar.sup.1 and Ar.sup.2 are the same or different and represent a substituted or unsubstituted aromatic group, and X represents —CH.sub.2O— or —CH═CH—, its salt, or their solvate, and a combined preparation for simultaneous, separate, or sequential administration in treating or preventing HIV-1 infection, comprising two separate preparations: (a) a preparation comprising a compound represented by the formula (I), its salt, or their solvate, and (b) a preparation comprising an anti-HIV-1 drug.

The present invention relates to a combination product and its use in therapy.

The present invention relates to a combination product and its use in therapy.

The present invention relates to a new application of phosphodiesterase inhibitors for couple infertility treatment which forms an effective alternative to the invasive assisted reproductive techniques such as conjugal artificial insemination and which consists of the transvaginal administration of a phosphodiesterase inhibitor immediately before and/or after coitus. It also relates to dosage forms suitable for the intravaginal administration of phosphodiesterase inhibitors.

Disclosed herein are methods, compositions and kits for treating a viral infection, for example, COVID-19, MERS and SARS. The disclosed compositions provide for enhanced delivery of the disclosed antiviral agents.

In one aspect, the invention provides compounds of Formula (I) or (II): (I) or (II) and pharmaceutically acceptable salts and solvates thereof, wherein R.sup.1, R.sup.2a, R.sup.2b, R.sup.3, R.sup.4, Z and G are defined as set forth in the disclosure. The invention also provides compounds of Formulae A and B and pharmaceutically acceptable salts and solvates thereof. Other aspects of the invention include the use of compounds of Formulae I, II, A, and B, and pharmaceutically acceptable salts and solvates thereof for the treatment of disorders responsive to modulation of one or more opioid receptors. In certain embodiments, the Compounds of the Invention are useful for treating pain.

##STR00001##

In one aspect, the invention provides compounds of Formula (I) or (II): (I) or (II) and pharmaceutically acceptable salts and solvates thereof, wherein R.sup.1, R.sup.2a, R.sup.2b, R.sup.3, R.sup.4, Z and G are defined as set forth in the disclosure. The invention also provides compounds of Formulae A and B and pharmaceutically acceptable salts and solvates thereof. Other aspects of the invention include the use of compounds of Formulae I, II, A, and B, and pharmaceutically acceptable salts and solvates thereof for the treatment of disorders responsive to modulation of one or more opioid receptors. In certain embodiments, the Compounds of the Invention are useful for treating pain.

##STR00001##

An aqueous composition having an excellent antiseptic effect is provided. An aqueous composition comprising a compound represented by Formula (1), wherein X represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, and a quaternary ammonium surfactant.